Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Top Cited Papers
- 19 July 2017
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 13 (8), 841-849
- https://doi.org/10.1016/j.jalz.2017.06.2266
Abstract
Introduction Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid‐binding positron emission tomography studies, are limited by cost and availability. There is a need for a more practical amyloid β (Aβ) biomarker for central nervous system amyloid deposition. Methods We adapted our previously reported stable isotope labeling kinetics protocol to analyze the turnover kinetics and concentrations of Aβ38, Aβ40, and Aβ42 in human plasma. Results Aβ isoforms have a half‐life of approximately 3 hours in plasma. Aβ38 demonstrated faster turnover kinetics compared with Aβ40 and Aβ42. Faster fractional turnover of Aβ42 relative to Aβ40 and lower Aβ42 and Aβ42/Aβ40 concentrations in amyloid‐positive participants were observed. Discussion Blood plasma Aβ42 shows similar amyloid‐associated alterations as we have previously reported in cerebrospinal fluid, suggesting a blood‐brain transportation mechanism of Aβ. The stability and sensitivity of plasma Aβ measurements suggest this may be a useful screening test for central nervous system amyloidosis.Funding Information
- MetLife Foundation
- AbbVie
- Amgen
- AstraZeneca
- Biogen
- Eisai
- Pfizer
- Sanofi
- Avid Radiopharmaceuticals
This publication has 18 references indexed in Scilit:
- Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation CarriersScience Translational Medicine, 2013
- Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kineticsAnalytical Biochemistry, 2013
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010Journal of Neuropathology and Experimental Neurology, 2012
- Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variantsNeurobiology of Aging, 2011
- Association of Plasma β-Amyloid Level and Cognitive Reserve With Subsequent Cognitive DeclineJAMA, 2011
- Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivoNature Medicine, 2006
- LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ IsoformsNeuron, 2004
- Plasma Aβ40 and Aβ42 and Alzheimer’s diseaseNeurology, 2003
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E GenotypeArchives of Neurology, 1998